Sodium bicarbonate supplementation and urinary TGF-β1 in nonacidotic diabetic kidney disease: A randomized, controlled trial
Clinical Journal of the American Society of Nephrology Feb 14, 2020
Raphael KL, Greene T, Wei G, et al. - By performing this randomized, double-blinded, placebo-controlled study, researchers determined how sodium bicarbonate can influence kidney fibrosis as well as injury markers in people with diabetic kidney disease and normal serum total CO2. Participants were 74 US veterans, suffering from type 1 or 2 diabetes mellitus. The study sample had eGFR of 15–89 ml/min per 1.73 m2, urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g, and serum total CO2 of 22–28 meq/L. For 6 months, oral sodium bicarbonate (0.5 meq/kg lean body wt per day; n = 35) or placebo (n = 39) was given to the participants. Alteration in urinary TGF-β1-to-creatinine, from baseline to months 3 and 6, was evaluated as the primary outcome. Findings revealed no significant decrease in urinary TGF-β1, kidney injury molecule-1, fibronectin, neutrophil gelatinase-associated lipocalin, or UACR was brought about by sodium bicarbonate over 6 months when administered to patients with nonacidotic diabetic kidney disease.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries